Erasca (NASDAQ:ERAS) Trading Up 8.5% – Time to Buy?

Shares of Erasca, Inc. (NASDAQ:ERAS) traded up 8.5% on Wednesday . The stock traded as high as $14.44 and last traded at $14.5160. 710,184 shares changed hands during mid-day trading, a decline of 89% from the average daily volume of 6,629,932 shares. The stock had previously closed at $13.38.

Key Headlines Impacting Erasca

Here are the key news stories impacting Erasca this week:

• Positive Sentiment: No clearly positive company-specific catalysts were reported in the recent news flow.
• Neutral Sentiment: Several law firms issued reminders about the August 10, 2026 deadline for investors to seek lead-plaintiff status in the pending class action. Article Title
• Neutral Sentiment: The class action centers on alleged securities-law violations during the January 14, 2025 to April 26, 2026 period, but the articles do not provide a court ruling or financial settlement yet. Article Title
• Negative Sentiment: Allegations that Erasca concealed adverse trial information and made misleading comparisons in its ERAS-0015 program increase litigation risk and are likely hurting investor confidence. Article Title

Wall Street Analyst Weigh In

ERAS has been the subject of several recent research reports. Guggenheim boosted their price target on Erasca from $12.00 to $20.00 and gave the company a “buy” rating in a research note on Monday, March 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Erasca in a research report on Thursday, June 11th. JPMorgan Chase & Co. lifted their target price on shares of Erasca from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, March 18th. Stifel Nicolaus boosted their target price on shares of Erasca from $20.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, April 27th. Finally, Wolfe Research set a $16.00 price target on shares of Erasca in a research note on Thursday, June 4th. Seven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Erasca presently has an average rating of “Moderate Buy” and a consensus price target of $20.11.

Erasca Price Performance

The company has a market cap of $4.25 billion, a price-to-earnings ratio of -14.70 and a beta of 0.73. The firm has a fifty day simple moving average of $13.93 and a 200 day simple moving average of $11.32.

Erasca (NASDAQ:ERAS) last released its earnings results on Monday, May 11th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.48). Analysts expect that Erasca, Inc. will post -0.55 earnings per share for the current year.

Insider Buying and Selling at Erasca

In other news, insider Ebun Garner sold 80,000 shares of the firm’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $16.40, for a total value of $1,312,000.00. Following the sale, the insider owned 25,076 shares in the company, valued at approximately $411,246.40. This trade represents a 76.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 14.20% of the company’s stock.

Hedge Funds Weigh In On Erasca

Large investors have recently bought and sold shares of the stock. VR Adviser LLC grew its position in Erasca by 10.1% in the 2nd quarter. VR Adviser LLC now owns 17,857,083 shares of the company’s stock worth $22,678,000 after purchasing an additional 1,640,867 shares during the last quarter. Paradigm Biocapital Advisors LP increased its holdings in shares of Erasca by 4.4% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 14,159,095 shares of the company’s stock worth $52,672,000 after purchasing an additional 599,078 shares during the period. Vanguard Group Inc. raised its position in shares of Erasca by 0.9% during the third quarter. Vanguard Group Inc. now owns 12,811,832 shares of the company’s stock valued at $27,930,000 after buying an additional 116,235 shares during the last quarter. Vivo Capital LLC raised its position in shares of Erasca by 31.0% during the first quarter. Vivo Capital LLC now owns 12,151,480 shares of the company’s stock valued at $196,611,000 after buying an additional 2,878,052 shares during the last quarter. Finally, Siren L.L.C. lifted its stake in shares of Erasca by 28.4% in the first quarter. Siren L.L.C. now owns 11,244,246 shares of the company’s stock valued at $181,932,000 after buying an additional 2,486,997 shares during the period. 67.78% of the stock is currently owned by institutional investors and hedge funds.

Erasca Company Profile

Erasca, Inc is a clinical?stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene?driven and immuno?oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.